Related Experiment Videos
Differences in F36VMpl-based in vivo selection among large animal models
Robert E Richard1, R Angelo De Claro, James Yan
1Division of Hematology, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|September 29, 2004
Summary
Baboon hematopoietic cells show limited response to a gene therapy selection system previously effective in mice, dogs, and humans. This variability impacts the development of new gene therapies using large animal models.
Area of Science:
- Hematology
- Gene Therapy
- Translational Medicine
Background:
- Animal models are crucial for advancing human therapeutics.
- Gene therapy approaches often show model-specific efficacy.
- Large animal models are underutilized for comparative gene therapy studies.
Purpose of the Study:
- To evaluate a novel gene therapy selection system in baboons.
- To compare baboon hematopoietic cell response to other species.
- To assess the utility of baboons as a large animal model for gene therapy.
Main Methods:
- Utilized a conditional thrombopoietin receptor derivative (F36Vmpl) activated by a chemical inducer of dimerization (CID).
- Assessed proliferation of cultured baboon hematopoietic cells in response to F36Vmpl.
- Administered CID in vivo to baboons and monitored hematopoietic cell frequency.
Main Results:
- Baboon hematopoietic cells exhibited a minor and variable response to the F36Vmpl signal in vitro.
- In vivo CID administration resulted in modest and inconsistent increases in transduced cells in baboons.
- Observed significant differences compared to robust responses in mice and dogs.
Conclusions:
- The F36Vmpl/CID system shows limited efficacy in baboon hematopoietic cells.
- Baboons may not be a suitable model for this specific gene therapy approach.
- Findings highlight the need for careful selection of large animal models in gene therapy development.